[go: up one dir, main page]

CL2019003562A1 - Derivados esteroideos con actividad terapéutica. - Google Patents

Derivados esteroideos con actividad terapéutica.

Info

Publication number
CL2019003562A1
CL2019003562A1 CL2019003562A CL2019003562A CL2019003562A1 CL 2019003562 A1 CL2019003562 A1 CL 2019003562A1 CL 2019003562 A CL2019003562 A CL 2019003562A CL 2019003562 A CL2019003562 A CL 2019003562A CL 2019003562 A1 CL2019003562 A1 CL 2019003562A1
Authority
CL
Chile
Prior art keywords
therapeutic activity
diseases
steroid derivatives
pharmaceutically acceptable
acceptable salts
Prior art date
Application number
CL2019003562A
Other languages
English (en)
Inventor
Leena Hirvelä
Marjo Hakola
Tero Linnanen
Pasi Koskimies
Camilla Stjernschantz
Original Assignee
Forendo Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forendo Pharma Ltd filed Critical Forendo Pharma Ltd
Publication of CL2019003562A1 publication Critical patent/CL2019003562A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0016—Oximes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0044—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 with an estrane or gonane skeleton, including 18-substituted derivatives and derivatives where position 17-beta is substituted by a carbon atom not directly bonded to another carbon atom and not being part of an amide group

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

LA INVENCIÓN SE RELACIONA CON COMPUESTOS DE FÓRMULA (I) Y SUS SALES FARMACÉUTICAMENTE ACEPTABLES, DONDE R1 A R4 CORRESPONDEN A LA DEFINICIÓN DE LAS REIVINDICACIONES. LA INVENCIÓN SE RELACIONA ADEMÁS CON SU USO COMO INHIBIDORES DE 17Β-HSD1 Y EN EL TRATAMIENTO O LA PREVENCIÓN DE ENFERMEDADES O TRASTORNOS DEPENDIENTES DE HORMONAS ESTEROIDEAS, COMO ENFERMEDADES O TRASTORNOS DEPENDIENTES DE HORMONAS ESTEROIDEAS QUE REQUIERAN LA INHIBICIÓN DE LA ENZIMA 17Β-HSD1 Y/O LA REDUCCIÓN DE LA CONCENTRACIÓN DE ESTRADIOL ENDÓGENO. LA PRESENTE INVENCIÓN SE RELACIONA ADEMÁS CON LA PREPARACIÓN DE LOS COMPUESTOS MENCIONADOS Y CON COMPOSICIONES FARMACÉUTICAS QUE COMPRENDE COMO INGREDIENTES ACTIVOS UNO O MÁS DE LOS COMPUESTOS MENCIONADOS O SUS SALES FARMACÉUTICAMENTE ACEPTABLES.
CL2019003562A 2017-06-08 2019-12-05 Derivados esteroideos con actividad terapéutica. CL2019003562A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20175530 2017-06-08

Publications (1)

Publication Number Publication Date
CL2019003562A1 true CL2019003562A1 (es) 2020-06-12

Family

ID=62716091

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019003562A CL2019003562A1 (es) 2017-06-08 2019-12-05 Derivados esteroideos con actividad terapéutica.

Country Status (26)

Country Link
US (5) US10717761B2 (es)
EP (1) EP3634975B1 (es)
JP (3) JP7064515B2 (es)
KR (1) KR102420512B1 (es)
CN (2) CN115716860A (es)
AU (1) AU2018279205B2 (es)
CA (1) CA3066196C (es)
CL (1) CL2019003562A1 (es)
DK (1) DK3634975T3 (es)
EA (1) EA201992826A1 (es)
ES (1) ES2988187T3 (es)
FI (1) FI3634975T3 (es)
HR (1) HRP20240679T1 (es)
HU (1) HUE066375T2 (es)
IL (2) IL294140B2 (es)
LT (1) LT3634975T (es)
MX (2) MX2022000747A (es)
NZ (1) NZ760155A (es)
PL (1) PL3634975T3 (es)
PT (1) PT3634975T (es)
RS (1) RS65529B1 (es)
SG (1) SG11201911776PA (es)
SI (1) SI3634975T1 (es)
UA (1) UA126342C2 (es)
WO (1) WO2018224736A2 (es)
ZA (1) ZA201908404B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210114390A (ko) * 2018-12-05 2021-09-23 포렌도 파마 리미티드 17-hsd1의 억제제로서의 피라졸 고리와 위치 16(17)에서 축합된 에스트라-1,3,5(10)-트리엔 화합물
CN114644673B (zh) * 2020-12-19 2023-12-26 上海喀露蓝科技有限公司 一种雌二醇衍生物、其制备方法及其在医药上的用途
CN117264008A (zh) * 2022-06-15 2023-12-22 中国科学院大连化学物理研究所 一种化合物及应用和抑制剂与药物
WO2025185710A1 (zh) * 2024-03-08 2025-09-12 长春金赛药业有限责任公司 17β-HSD1抑制剂化合物、药物组合物及其应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2000125533A (ru) 1998-03-11 2002-10-20 Эндорешерш, Инк. (Ca) Ингибиторы 17-бета-гидроксистероиддегидрогеназ 5 и 3 типа и способы их применения
GB9929302D0 (en) 1999-12-11 2000-02-02 Univ Cardiff Benzyl tetralins compositions and uses thereof
AR036492A1 (es) 2001-09-06 2004-09-15 Schering Corp Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3, composiciones farmaceuticas y el uso de dichos inhibidores para la elaboracion de un medicamento para el tratamiento de enfermedades androgeno dependientes
PE20030705A1 (es) 2001-10-17 2003-08-21 Schering Corp Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes
JP4614770B2 (ja) 2002-11-18 2011-01-19 シェーリング コーポレイション アンドロゲン依存性疾患を処置するための１７β−ヒドロキシステロイドデヒドロゲナーゼタイプ３インヒビター
US7053091B2 (en) 2002-12-17 2006-05-30 Schering Corporation 17 β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
US7015211B2 (en) 2003-03-21 2006-03-21 Yale University 15α-substituted estradiol carboxylic acid esters as locally active estrogens
GB0306718D0 (en) 2003-03-24 2003-04-30 Sterix Ltd Compound
US20040224935A1 (en) 2003-04-07 2004-11-11 Endorecherche, Inc. Topical antiandrogenic steroids
US7754709B2 (en) 2003-06-10 2010-07-13 Solvay Pharmaceuticals Bv Tetracyclic thiophenepyrimidinone compounds as inhibitors of 17β hydroxysteroid dehydrogenase compounds
US7465739B2 (en) 2003-06-10 2008-12-16 Solvay Pharmaceuticals B.V. Compounds and their use in therapy
US8088758B2 (en) * 2003-11-12 2012-01-03 Abbott Products Gmbh 17β-hydroxysteroid dehydrogenase type I inhibitors
TWI331154B (en) 2003-11-12 2010-10-01 Solvay Pharm Gmbh Novel 17-hydroxysteroid dehydrogenase type i inhibitors
US7378426B2 (en) 2004-03-01 2008-05-27 Bristol-Myers Squibb Company Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
DE102004032673A1 (de) 2004-07-02 2006-01-26 Schering Ag Neue 2-substituierte D-Homo-estra-1,3,5(10)-triene als Inhibitoren der 17ß-Hydroxysteroiddehydrogenase Typ 1
DE102004032674A1 (de) 2004-07-02 2006-01-26 Schering Ag Neue 2-substituierte Estra-1,3,5(10)-trien-17-one als Inhibitoren der 17β-Hydroxysteroiddehydrogenase Typ 1
US7575828B2 (en) 2004-07-23 2009-08-18 Kim Manufacturing Co. Modular rack assemblies for sealed lead acid batteries
UA89964C2 (ru) 2004-09-08 2010-03-25 Н.В. Органон 15β-ЗАМЕЩЕННЫЕ СТЕРОИДЫ, КОТОРЫЕ ИМЕЮТ СЕЛЕКТИВНУЮ ЭСТРОГЕННУЮ АКТИВНОСТЬ
US8030298B2 (en) 2005-05-26 2011-10-04 Abbott Products Gmbh 17β-HSD1 and STS inhibitors
CN102796160A (zh) 2005-05-26 2012-11-28 索尔瓦药物有限公司 17β-HSD1和STS抑制剂
WO2008034796A2 (en) 2006-09-19 2008-03-27 Solvay Pharmaceuticals Gmbh Estratriene derivatives and their uses as 17beta-hydr0xyster0id dehydrogenase inhibitors
CA2671075A1 (en) 2006-11-30 2008-06-05 Solvay Pharmaceuticals Gmbh Substituted estratrien derivatives as 17beta hsd inhibitors
US9284345B2 (en) 2007-04-12 2016-03-15 Endorecherche, Inc. 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators
AU2009316478A1 (en) 2008-11-20 2010-05-27 President And Fellows Of Harvard College Fluorination of organic compounds
EP2688901B1 (en) * 2011-03-25 2019-05-08 Université Laval INHIBITORS OF 17ß-HSD1, 17ß-HSD3 AND 17ß-HSD10
EP3013845B1 (en) * 2013-06-25 2020-03-18 Forendo Pharma Ltd Therapeutically active estratrienthiazole derivatives as inhibitors of 17b-hydroxysteroid dehydrogenase, type 1
CN105518015B (zh) * 2013-06-25 2017-09-15 佛恩多制药有限公司 治疗活性的作为17β‑羟基类固醇脱氢酶抑制剂的17‑氮取代雌三烯噻唑衍生物
US9850272B2 (en) * 2013-06-25 2017-12-26 Forendo Pharma Ltd. Therapeutically active estratrienthiazole derivatives as inhibitors of 17.beta-hydroxy-steroid dehydrogenase, type 1
WO2016102775A1 (en) * 2014-12-23 2016-06-30 Forendo Pharma Ltd PRODRUGS OF 17β-HSD1 -INHIBITORS
WO2016102776A1 (en) * 2014-12-23 2016-06-30 Forendo Pharma Ltd Prodrugs of 17.beta.-hsd1 -inhibitors

Also Published As

Publication number Publication date
ZA201908404B (en) 2023-11-29
PT3634975T (pt) 2024-05-20
US20250263431A1 (en) 2025-08-21
ES2988187T3 (es) 2024-11-19
SG11201911776PA (en) 2020-01-30
IL294140B1 (en) 2024-05-01
MX391234B (es) 2025-03-21
RS65529B1 (sr) 2024-06-28
HUE066375T2 (hu) 2024-07-28
CN115716860A (zh) 2023-02-28
JP7064515B2 (ja) 2022-05-10
KR20200023362A (ko) 2020-03-04
US20220127303A1 (en) 2022-04-28
BR112019025782A2 (pt) 2020-06-23
AU2018279205B2 (en) 2021-04-15
FI3634975T3 (fi) 2024-05-03
JP7664359B2 (ja) 2025-04-17
MX2022000747A (es) 2023-01-24
CA3066196A1 (en) 2018-12-13
IL294140B2 (en) 2024-09-01
JP2022065030A (ja) 2022-04-26
PL3634975T3 (pl) 2024-07-01
WO2018224736A2 (en) 2018-12-13
WO2018224736A3 (en) 2019-01-17
EP3634975B1 (en) 2024-02-28
DK3634975T3 (da) 2024-05-27
KR102420512B1 (ko) 2022-07-13
US20180354984A1 (en) 2018-12-13
CN110945007A (zh) 2020-03-31
US20200317718A1 (en) 2020-10-08
US10717761B2 (en) 2020-07-21
CN110945007B (zh) 2022-11-18
HRP20240679T1 (hr) 2024-08-16
NZ760155A (en) 2022-09-30
SI3634975T1 (sl) 2024-06-28
UA126342C2 (uk) 2022-09-21
US11254703B2 (en) 2022-02-22
JP7401576B2 (ja) 2023-12-19
IL271218A (en) 2020-01-30
LT3634975T (lt) 2024-06-25
MX2019014677A (es) 2022-04-01
AU2018279205A1 (en) 2020-01-16
CA3066196C (en) 2023-08-29
JP2024028916A (ja) 2024-03-05
EP3634975A2 (en) 2020-04-15
JP2020522539A (ja) 2020-07-30
US20240309043A1 (en) 2024-09-19
IL294140A (en) 2022-08-01
EA201992826A1 (ru) 2020-05-14

Similar Documents

Publication Publication Date Title
CL2021000907A1 (es) Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1 (divisional de solicitud n° 01501-2020)
CL2019003562A1 (es) Derivados esteroideos con actividad terapéutica.
CO2020005887A2 (es) Compuestos policíclicos como inhibidores alostéricos de shp2
ECSP21004787A (es) Inhibidores de inflamasoma nlrp3
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
CR20170563A (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso.
BR112015020302A2 (pt) derivado de pirazol
NI201900099A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP19083621A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
NI201900098A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP19083640A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
EA201690077A1 (ru) Терапевтически активные производные эстратриен-тиазола
CL2019001586A1 (es) Insulina que contiene composiciones farmacéuticas.
MX381041B (es) Compuesto cíclico tipo cumarina como inhibidor de mek y su uso.
MX2022000646A (es) Derivados de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-4 ,5,6,7- tetrahidrobenzofuran-2-sulfonamida y compuestos relacionados como moduladores de nlpr3 para el tratamiento de esclerosis múltiple (ms).
CL2019002480A1 (es) Derivados de pirazol como inhibidores de bromodominio.
CO2021000229A2 (es) Compuestos de pirazol e imidazol para la inhibición de il-17 y rorgamma
BR112022002436A2 (pt) Composição farmacêutica oral contendo composto heterocíclico
MX2019000806A (es) Composicion vaginal que comprende una combinacion de estrogeno y vitamina d.
BR112019024804A2 (pt) compostos bicíclicos 5,6-fundidos e composições para o tratamento de doenças parasíticas
CL2021001468A1 (es) Derivados esteroideos con actividad terapéutica
CL2020002398A1 (es) Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida ("tcd")
BR112019017314A2 (pt) composições farmacêuticas para terapia de combinação
MX2021011979A (es) Derivados del isocromeno como inhibidores de la fosfoinositida 3-cinasa.